Chaganti Raju S.K. Form 3 April 04, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

(Print or Type Responses)

1. Name and Address of Reporting

^ -			Statement (Month/Day/	Vaor)	CANCER	CANCER GENETICS, INC [CGIX]				
(Last) 201 ROUTE FLOOR	(First)	(Middle) H, 2ND	04/04/2013		Person(s) to I	aship of Reporting to Issuer eck all applicable)		5. If Amendment, Date Original Filed(Month/Day/Year)		
RUTHERFO	(Street) RD, NJÂ	07070			_X_ Director Officer (give title below	or 10% Other w) (specify below)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)		Table I - N	Non-Derivat	ive Securiti	ies Be	neficially Owned		
1.Title of Securi (Instr. 4)	ty			2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr			
Common Sto	ck, par valı	ue \$0.0001	per share	183,977		D	Â			
Common Sto	ck, par valı	ue \$0.0001	per share	60,000		I	By li	mited liability company		
Common Sto	ck, par valı	ue \$0.0001	per share	97,826		I	By s	pouse		
Common Sto	ck, par valı	ue \$0.0001	per share	30,000		I	-	teeta R. Chaganti 2011 tor Retained Annuity t#1		
Common Sto	ck, par valı	ue \$0.0001	per share	33,494		I	•	teeta R. Chaganti 2011 tor Retained Annuity t#2		
Common Sto	ck, par valı	ue \$0.0001	per share	20,000		I	•	Raju Chaganti 2011 Grantor ined Annuity Trust		

SEC 1473 (7-02)

Edgar Filing: Chaganti Raju S.K. - Form 3

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable			Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Stock Option (right to buy)	(1)	03/31/2019	Common Stock, par value \$0.0001 per share	100,000	\$ 4	D	Â	
Stock Option (right to buy)	(2)	09/14/2020	Common Stock, par value \$0.0001 per share	36,000	\$ <u>(2)</u>	D	Â	
Convertible Note	(3)	(3)	Common Stock, par value \$0.0001 per share	(3)	\$ <u>(3)</u>	D	Â	

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Othe		
Chaganti Raju S.K. 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD, NJ 07070	ÂX	Â	Â	Â		

Signatures

/s/ Raju S.K. Chaganti	04/04/2013		
**Signature of Reporting Person	Date		

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was fully vested and exercisable on April 1, 2009.
- This option is currently vested and exercisable as to 30,000 shares. The remaining shares will vest and become exercisable in equal quarterly installments. The exercise price will be equal to the initial public offering price.
- The reporting person agreed to convert \$100,000 of the outstanding principal balance under the note plus all accrued and unpaid interest (3) thereon into shares of common stock of Cancer Genetics. Inc. (the "Company") upon consummation of the Company's initial public
- (3) thereon into shares of common stock of Cancer Genetics, Inc. (the "Company") upon consummation of the Company's initial public offering at a conversion price equal to the initial public offering price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.